Join our email list!

Get daily updates delivered to your inbox
Thank you for subscribing

Zinbryta Approval Process and Possible Side Effects


On May 27, 2016, Zinbryta (daclizumab) was approved for the treatment of adults with relapsing multiple sclerosis (MS).

However, there’s another side of the usage of this treatment that’s being discussed. Multiple Sclerosis News Today’s contributor blogger and multiple sclerosis (MS) patient, Ian Franks, questions the possible side effects of Zinbryta: “Would you agree to be treated with an MS disease-modifying therapy that has been developed to help you but has side effects that could, maybe only rarely but still could, lead to serious illness or even death?

Read his views on the subject here.

Recently Biogen and AbbVie also announced that Zinbryta received marketing authorization by the European Commission.

Learn more about the news of the now approved treatment across most of Europe for adults with relapsing forms of multiple sclerosis (MS).

In this MD Magazine TV video, listen to a brief introduction to Zinbryta from the month before its FDA approval.

Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *